Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor, Zoliflodacin

Journal of Clinical Microbiology

Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D., Arlene C. Seña, M.D., M.P.H., Jill Long, M.D., M.P.H., Michael R. Wierzbicki, Ph.D., Hannah Kwak, M.H.S., Shacondra M. Johnson, B.S.P.H., Kenneth Lawrence, Pharm.D., and John Mueller, Ph.D.

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

New England Journal of Medicine

John O' Donnell, Ken Lawrence, Karthick Vishwanathan, Vinayak Hosagrahara, John P. Mueller

Single-dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

AAC Accepted Manuscript posted online October 29, 2018

Anthony D. Cristillo, PhD, MS; Claire C. Bristow, PhD, MPH, MSc; Elizabeth Torrone, MSPH, PhD; Jo-Anne Dillon, MSc, PhD, FCAHS, FRSC; Robert D. Kirkcaldy, MD, MPH , Huan Dong, MS; Yonatan H. Grad, MD, PhD; Robert A. Nicholas, PhD; Peter A. Rice, MD; Kenneth Lawrence, PharmD; David Oldach, MD, FIDSA; William Maurice Shafer, PhD; Pei Zhou, PhD; Teodora E. Wi, MD; Sheldon R. Morris, MD, MPH; and Jeffrey D. Klausner, MD, MPH

Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting

Journal of Sexually Transmitted Diseases

Damião Gouveia, A.C., Unemo, M. and Jensen, J.S.

In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains

J Antimicrobial Chemotherapy doi:10.1093/jac/dky022 (2018)

Papp JR, Lawrence K, Sharpe S, Mueller J, Kirkcaldy R

In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione

International Journal of Antimicrobial Agents (2016)

Giacobbe R, Huband M, deJonge B, Bradford P

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914

Diagnostic Microbiology and Infectious Disease (2016)

Guo J, Joubran C, Luzietti RA Jr, Basarab GS, Grimm SW, Vishwanathan K

Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents

Xenobiotica (2016)

Foerster S, Golparian D, Jacobsson S, Hathaway L, Low N, Shafer W, Althaus C, Unemo M

Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae

Frontiers in Microbiology (2015)

Su XH, Wang BX, Le WJ, Liu YR, Wan C, Li S, Alm RA, Mueller JP, Rice PA

Multidrug resistant Neisseria gonorrhoeae from Nanjing are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)

Antimicrobial Agents Chemotherapy (2015)